董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Antoine Papiernik | 男 | Director | 52 | 未披露 | 未持股 | 2019-02-08 |
| Frederic Moll | 男 | Director | 67 | 1.50万美元 | 未持股 | 2019-02-08 |
| Laura A. Francis | 女 | Director | 52 | 未披露 | 未持股 | 2019-02-08 |
| F. T. Jay Watkins | 男 | Director | 66 | 1.50万美元 | 未持股 | 2019-02-08 |
| Colin Cahill | 男 | Director | 43 | 未披露 | 未持股 | 2019-02-08 |
| Marc Andre Marcotte | 男 | Director | 44 | 未披露 | 未持股 | 2019-02-08 |
| Douglas Godshall | 男 | President, Chief Executive Officer and Director | 54 | 51.09万美元 | 未持股 | 2019-02-08 |
| C. Raymond Larkin, Jr. | 男 | Chairman and Director | 70 | 未披露 | 未持股 | 2019-02-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dan Puckett | 男 | Chief Financial Officer and Secretary | 55 | 42.98万美元 | 未持股 | 2019-02-08 |
| Isaac Zacharias | 男 | Chief Commercial Officer | 44 | 90.79万美元 | 未持股 | 2019-02-08 |
| Douglas Godshall | 男 | President, Chief Executive Officer and Director | 54 | 51.09万美元 | 未持股 | 2019-02-08 |
董事简历
中英对照 | 中文 | 英文- Antoine Papiernik
-
Antoine Papiernik，2014年1月起，他担任我公司监事会成员。他是Sofinnova Partners的管理合伙人，于1997年加入该公司。他曾担任许多上市公司的最初投资人和活跃的董事会成员，包括Actelion, Addex, Auris Medical, Orexo, NovusPharma（被CTI, Movetis收购，又被Shire收购）， Mainstay, Pixium和 Stentys， 上述公司分别在苏黎世证交所（Zurich Stock Exchange）、纳斯达克全球市场（NASDAQ Global Market）、斯德哥尔摩证交所（Stockholm Stock Exchange）、Milan Nuovo Mercato、比利时证交所（Belgium Stock Exchange）、都柏林证交所（Dublin Stock Exchange）和泛欧证交所（EuroNext Paris）上市，还包括Cotherix （在纳斯达克首次公开募股，后被Actelion收购）， CoreValve （被Medtronic收购）， Fovea （被 Sanofi Aventis收购）和Ethical Oncology Science （EOS， 被Clovis Oncology收购）。 他还投资并担任私人公司MD Start, ReCor, Shockwave Medical和Reflexion Medical的董事会成员。他在宾夕法尼亚大学沃顿商学院（Wharton School of Business, University of Pennsylvania）获得工商管理硕士学位。
Antoine Papiernik has served on our supervisory board since January 2014. Mr. Papiernik is managing partner at Sofinnova Partners, which he joined in 1997 and was appointed chairman in 2017. Mr. Papiernik has been an initial investor and active board member in public companies like Actelion, Addex, Auris Medical, Shockwave Medical Inc., Orexo, NovusPharma then sold to CTI, Movetis (then sold to Shire), Mainstay Medical, Pixium Vision and Stentys, which went public respectively on the Zurich Stock Exchange, the NASDAQ Global Market, the Stockholm Stock Exchange, the Milan Nuovo Mercato, the Belgium Stock Exchange, the Dublin Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), Core Valve (sold to Medtronic), Fovea (sold to Sanofi Aventis) Ethical Oncology Science (EOS, sold to ClovisOncology) and Recor Medical (sold to Otsuka). Mr. Papiernik is also a board member of private companies MedDay Pharmaceuticals, MD Start II, Reflexion Medical, Tissium (previously named Gecko Biomedical), SafeHeal, Highlife, Rgenix and Ablacare. Mr. Papiernik has an MBA degree from the Wharton School of Business, University of Pennsylvania. - Antoine Papiernik，2014年1月起，他担任我公司监事会成员。他是Sofinnova Partners的管理合伙人，于1997年加入该公司。他曾担任许多上市公司的最初投资人和活跃的董事会成员，包括Actelion, Addex, Auris Medical, Orexo, NovusPharma（被CTI, Movetis收购，又被Shire收购）， Mainstay, Pixium和 Stentys， 上述公司分别在苏黎世证交所（Zurich Stock Exchange）、纳斯达克全球市场（NASDAQ Global Market）、斯德哥尔摩证交所（Stockholm Stock Exchange）、Milan Nuovo Mercato、比利时证交所（Belgium Stock Exchange）、都柏林证交所（Dublin Stock Exchange）和泛欧证交所（EuroNext Paris）上市，还包括Cotherix （在纳斯达克首次公开募股，后被Actelion收购）， CoreValve （被Medtronic收购）， Fovea （被 Sanofi Aventis收购）和Ethical Oncology Science （EOS， 被Clovis Oncology收购）。 他还投资并担任私人公司MD Start, ReCor, Shockwave Medical和Reflexion Medical的董事会成员。他在宾夕法尼亚大学沃顿商学院（Wharton School of Business, University of Pennsylvania）获得工商管理硕士学位。
- Antoine Papiernik has served on our supervisory board since January 2014. Mr. Papiernik is managing partner at Sofinnova Partners, which he joined in 1997 and was appointed chairman in 2017. Mr. Papiernik has been an initial investor and active board member in public companies like Actelion, Addex, Auris Medical, Shockwave Medical Inc., Orexo, NovusPharma then sold to CTI, Movetis (then sold to Shire), Mainstay Medical, Pixium Vision and Stentys, which went public respectively on the Zurich Stock Exchange, the NASDAQ Global Market, the Stockholm Stock Exchange, the Milan Nuovo Mercato, the Belgium Stock Exchange, the Dublin Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), Core Valve (sold to Medtronic), Fovea (sold to Sanofi Aventis) Ethical Oncology Science (EOS, sold to ClovisOncology) and Recor Medical (sold to Otsuka). Mr. Papiernik is also a board member of private companies MedDay Pharmaceuticals, MD Start II, Reflexion Medical, Tissium (previously named Gecko Biomedical), SafeHeal, Highlife, Rgenix and Ablacare. Mr. Papiernik has an MBA degree from the Wharton School of Business, University of Pennsylvania.
- Frederic Moll
-
Frederic Moll自2011年以来一直担任我们的董事会成员。Moll博士自2002年11月以来是Restoration Robotics，Inc.的成员并担任董事会主席。Moll博士也是联合创始人，自2012年9月起担任Auris Health，Inc.的董事长兼首席执行官。Moll博士自2011年以来担任Circuit Therapeutics的领导职务。从2002年到2010年，他曾担任Hansen Medical公司（他也曾共同创立该公司）的首席执行官。在此之前，Moll博士共同创立了直觉外科公司，并从1995年到2002年担任其第一任首席执行官。Moll博士还联合创立了Endo-Therapeutics，Inc.和Origin，后者在被礼来公司（Eli Lilly&Company）收购后成为Guidant Corporation的一家运营公司。Moll博士在Intersectent，Inc.的董事会任职。Moll博士在加州大学伯克利分校（University of California at Berkeley）获得经济学学士学位，在斯坦福大学（Stanford University）获得管理学硕士学位，在华盛顿大学（University of Washington）获得医学博士学位。
Frederic Moll has served as a member of our board of directors since August 2011 and has served as Chair since March 2021. Since April 2019 Dr. Moll has served as Chief Development Officer for Johnson & Johnson Medical Devices Companies. Dr. Moll was also a co-founder, and, from September 2012 to 2019 was the Chairman and Chief Executive Officer of Auris Health, Inc. Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. Dr. Moll previously served as member and as Chairman of the board of Restoration Robotics, Inc., from November 2002 until its merger with Venus Concept in November 2019. He has also served on the boards of Shockwave Medical, Inc., since March 2011 where he is a member of the nominating and corporate governance committee, INSIGHTEC Ltd., since June 2020 where he is a member of the audit committee, and Lux Health Tech Acquisition Corp., since June 2020 where he is a member of the audit committee, and he previously served on the board of directors at IntersectENT, Inc. from March 2010 to February 2021 where he was a member of the nominating and corporate governance committee. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. in management from Stanford University and an M.D. from the University of Washington. - Frederic Moll自2011年以来一直担任我们的董事会成员。Moll博士自2002年11月以来是Restoration Robotics，Inc.的成员并担任董事会主席。Moll博士也是联合创始人，自2012年9月起担任Auris Health，Inc.的董事长兼首席执行官。Moll博士自2011年以来担任Circuit Therapeutics的领导职务。从2002年到2010年，他曾担任Hansen Medical公司（他也曾共同创立该公司）的首席执行官。在此之前，Moll博士共同创立了直觉外科公司，并从1995年到2002年担任其第一任首席执行官。Moll博士还联合创立了Endo-Therapeutics，Inc.和Origin，后者在被礼来公司（Eli Lilly&Company）收购后成为Guidant Corporation的一家运营公司。Moll博士在Intersectent，Inc.的董事会任职。Moll博士在加州大学伯克利分校（University of California at Berkeley）获得经济学学士学位，在斯坦福大学（Stanford University）获得管理学硕士学位，在华盛顿大学（University of Washington）获得医学博士学位。
- Frederic Moll has served as a member of our board of directors since August 2011 and has served as Chair since March 2021. Since April 2019 Dr. Moll has served as Chief Development Officer for Johnson & Johnson Medical Devices Companies. Dr. Moll was also a co-founder, and, from September 2012 to 2019 was the Chairman and Chief Executive Officer of Auris Health, Inc. Dr. Moll is also the Founding Partner of Sonder Capital Management, LLC, a healthcare venture capital investment firm. Dr. Moll previously served as member and as Chairman of the board of Restoration Robotics, Inc., from November 2002 until its merger with Venus Concept in November 2019. He has also served on the boards of Shockwave Medical, Inc., since March 2011 where he is a member of the nominating and corporate governance committee, INSIGHTEC Ltd., since June 2020 where he is a member of the audit committee, and Lux Health Tech Acquisition Corp., since June 2020 where he is a member of the audit committee, and he previously served on the board of directors at IntersectENT, Inc. from March 2010 to February 2021 where he was a member of the nominating and corporate governance committee. Dr. Moll received a B.A. in economics from the University of California at Berkeley, an M.S. in management from Stanford University and an M.D. from the University of Washington.
- Laura A. Francis
-
LauraA.Francis自2015年5月起担任我们的首席财务官。在加入我们之前，Francis女士于2012年12月至2014年9月担任Auxogyn，Inc.（一家女性健康公司）的首席财务官。2004年9月至2012年12月，Francis女士担任生命科学试剂公司Promega Corporation的财务Vice President、首席财务官和财务主管。2002年3月至2004年9月，Francis女士担任Bruker Biosciences Corporation（一家公共生命科学仪器公司）的首席财务官。2001年5月至2002年3月，Francis女士担任Nutra-Park Inc.（一家农业生物技术公司）的首席运营官和首席财务官。Francis从1999年4月到2001年5月担任Hypercosm，Inc.（一家软件公司）首席财务官。Francis从1995年10月到1999年4月担任McKinsey&Company（一家咨询公司）业务经理。在她的职业生涯早期，Francis女士是会计师事务所Coopers&Lybrand的审计经理。Francis女士在威斯康星大学（University of Wisconsin）获得工商管理学士学位，在斯坦福大学（Stanford University）获得工商管理硕士学位。她是加州不活跃的注册会计师。
Laura A. Francis has served as our Chief Financial Officer since May 2015. Prior to joining us, Ms. Francis was the Chief Financial Officer for Auxogyn, Inc., a women’s health company, from December 2012 to September 2014. From September 2004 to December 2012 Ms. Francis served as Vice President of Finance, Chief Financial Officer and Treasurer for Promega Corporation, a life science reagent company. From March 2002 to September 2004 Ms. Francis served as the Chief Financial Officer of Bruker BioSciences Corporation, a public life science instrumentation company. From May 2001 to March 2002 Ms. Francis served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., an agricultural biotechnology company. From April 1999 to May 2001 Ms. Francis was Chief Financial Officer of Hypercosm, Inc., a software company. From October 1995 to April 1999 Ms. Francis was an engagement manager with McKinsey & Company, a consulting firm. Early in her career, Ms. Francis was an audit manager with Coopers & Lybrand, an accounting firm. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant inactive in the State of California. - LauraA.Francis自2015年5月起担任我们的首席财务官。在加入我们之前，Francis女士于2012年12月至2014年9月担任Auxogyn，Inc.（一家女性健康公司）的首席财务官。2004年9月至2012年12月，Francis女士担任生命科学试剂公司Promega Corporation的财务Vice President、首席财务官和财务主管。2002年3月至2004年9月，Francis女士担任Bruker Biosciences Corporation（一家公共生命科学仪器公司）的首席财务官。2001年5月至2002年3月，Francis女士担任Nutra-Park Inc.（一家农业生物技术公司）的首席运营官和首席财务官。Francis从1999年4月到2001年5月担任Hypercosm，Inc.（一家软件公司）首席财务官。Francis从1995年10月到1999年4月担任McKinsey&Company（一家咨询公司）业务经理。在她的职业生涯早期，Francis女士是会计师事务所Coopers&Lybrand的审计经理。Francis女士在威斯康星大学（University of Wisconsin）获得工商管理学士学位，在斯坦福大学（Stanford University）获得工商管理硕士学位。她是加州不活跃的注册会计师。
- Laura A. Francis has served as our Chief Financial Officer since May 2015. Prior to joining us, Ms. Francis was the Chief Financial Officer for Auxogyn, Inc., a women’s health company, from December 2012 to September 2014. From September 2004 to December 2012 Ms. Francis served as Vice President of Finance, Chief Financial Officer and Treasurer for Promega Corporation, a life science reagent company. From March 2002 to September 2004 Ms. Francis served as the Chief Financial Officer of Bruker BioSciences Corporation, a public life science instrumentation company. From May 2001 to March 2002 Ms. Francis served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., an agricultural biotechnology company. From April 1999 to May 2001 Ms. Francis was Chief Financial Officer of Hypercosm, Inc., a software company. From October 1995 to April 1999 Ms. Francis was an engagement manager with McKinsey & Company, a consulting firm. Early in her career, Ms. Francis was an audit manager with Coopers & Lybrand, an accounting firm. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant inactive in the State of California.
- F. T. Jay Watkins
-
F.T.Jay Watkins自2013年以来一直担任我们的董事会成员。他此前曾于2017年5月至2019年1月担任我们的董事会主席。Watkins先生自2002年以来一直担任de Novo Ventures“；de Novo”；的董事总经理。在2002年加入De Novo之前，Watkins先生是Origin Medsystems，Inc.的联合创始人兼创始首席执行官，该公司是一家风险投资的医疗技术初创公司，直到1995年被Eli Lilly&Company收购。当礼来公司（Eli Lilly）将其医疗设备业务剥离为Guidant Corporation（&8220；Guidant&8221；）时，Watkins先生成为Guidant&8217；的管理委员会成员，并担任多个部门的总裁，包括微创外科集团，心脏和血管外科集团以及心律技术公司。沃特金斯还联合创立了Gyneare，Inc.，这是一家女性医疗保健公司，该公司被分拆上市，随后被强生公司收购。Watkins先生也是Compass，Guidant&8217；s Corporate Business Development and New Ventures Group的创始总裁。在那里他曾参与收购两家上市公司，并领导14家公司的风险投资。在加入Origin之前，Watkins先生还在几家初创企业担任管理职位，包括Microgenics（被Boehringer Manngheim收购），是麦肯锡公司（McKinsey&Company）的顾问。Watkins先生在哈佛商学院（Harvard Business School）获得工商管理硕士学位，在斯坦福大学（Stanford University）获得工商管理学士学位。
F. T. Jay Watkins has served as a member of our board of directors since 2013. He previously served as the Chairman of our board from May 2017 to January 2019. Mr. Watkins has been a Managing Director at De Novo Ventures “De Novo” since 2002. Prior to joining De Novo in 2002 Mr. Watkins was a co-founder and founding Chief Executive Officer of Origin Medsystems, Inc. “Origin”, a venture funded medical technology start-up, until its acquisition by Eli Lilly & Company “Eli Lilly” in 1995. When Eli Lilly spun out its medical device businesses as Guidant Corporation (“Guidant”), Mr. Watkins became a member of Guidant’s Management Committee and served as president of several divisions including the Minimally Invasive Surgery Group, the Cardiac and Vascular Surgery Group and Heart Rhythm Technologies. Mr. Watkins also co-founded Gynecare, Inc., a woman’s health care company, which was spun out, taken public and subsequently acquired by Johnson & Johnson. Mr. Watkins was also the founding president of Compass, Guidant’s corporate business development and new ventures group. where he was involved in the acquisition of two public companies and led venture investments in 14 companies. Prior to joining Origin, Mr. Watkins also held management positions in several start-ups, including Microgenics (acquired by Boehringer Manngheim) and was a consultant with McKinsey & Company. Mr. Watkins received his M.B.A. from Harvard Business School and his B.A. from Stanford University. - F.T.Jay Watkins自2013年以来一直担任我们的董事会成员。他此前曾于2017年5月至2019年1月担任我们的董事会主席。Watkins先生自2002年以来一直担任de Novo Ventures“；de Novo”；的董事总经理。在2002年加入De Novo之前，Watkins先生是Origin Medsystems，Inc.的联合创始人兼创始首席执行官，该公司是一家风险投资的医疗技术初创公司，直到1995年被Eli Lilly&Company收购。当礼来公司（Eli Lilly）将其医疗设备业务剥离为Guidant Corporation（&8220；Guidant&8221；）时，Watkins先生成为Guidant&8217；的管理委员会成员，并担任多个部门的总裁，包括微创外科集团，心脏和血管外科集团以及心律技术公司。沃特金斯还联合创立了Gyneare，Inc.，这是一家女性医疗保健公司，该公司被分拆上市，随后被强生公司收购。Watkins先生也是Compass，Guidant&8217；s Corporate Business Development and New Ventures Group的创始总裁。在那里他曾参与收购两家上市公司，并领导14家公司的风险投资。在加入Origin之前，Watkins先生还在几家初创企业担任管理职位，包括Microgenics（被Boehringer Manngheim收购），是麦肯锡公司（McKinsey&Company）的顾问。Watkins先生在哈佛商学院（Harvard Business School）获得工商管理硕士学位，在斯坦福大学（Stanford University）获得工商管理学士学位。
- F. T. Jay Watkins has served as a member of our board of directors since 2013. He previously served as the Chairman of our board from May 2017 to January 2019. Mr. Watkins has been a Managing Director at De Novo Ventures “De Novo” since 2002. Prior to joining De Novo in 2002 Mr. Watkins was a co-founder and founding Chief Executive Officer of Origin Medsystems, Inc. “Origin”, a venture funded medical technology start-up, until its acquisition by Eli Lilly & Company “Eli Lilly” in 1995. When Eli Lilly spun out its medical device businesses as Guidant Corporation (“Guidant”), Mr. Watkins became a member of Guidant’s Management Committee and served as president of several divisions including the Minimally Invasive Surgery Group, the Cardiac and Vascular Surgery Group and Heart Rhythm Technologies. Mr. Watkins also co-founded Gynecare, Inc., a woman’s health care company, which was spun out, taken public and subsequently acquired by Johnson & Johnson. Mr. Watkins was also the founding president of Compass, Guidant’s corporate business development and new ventures group. where he was involved in the acquisition of two public companies and led venture investments in 14 companies. Prior to joining Origin, Mr. Watkins also held management positions in several start-ups, including Microgenics (acquired by Boehringer Manngheim) and was a consultant with McKinsey & Company. Mr. Watkins received his M.B.A. from Harvard Business School and his B.A. from Stanford University.
- Colin Cahill
-
Colin Cahill自2015年5月以来一直担任我们的董事会成员。Cahill先生自2012年以来一直担任Venrock的副总裁，并专注于Venrock&8217；的公共和交叉生物技术基金。在加入Venrock之前，Cahill先生是Simpirica Spine，Inc.的联合创始人兼首席开发官，Simpirica&8221；是一家湾区医疗设备公司，专注于脊柱稳定设备的开发和商业化。从2006年到2009年，Cahill先生还担任Simpirica&8217；的首席执行官。在研究生院之前，Cahill先生在波士顿咨询集团（Boston Consulting Group）工作，担任战略顾问。Cahill先生在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，并在斯坦福大学（Stanford University）获得生物科学硕士学位。Cahill先生分别在斯坦福大学（Stanford University）获得生物科学和经济学的学士学位和学士学位。
Colin Cahill has served as a member of our board of directors since May 2015. Mr. Cahill has been Vice-President of Venrock since 2012 and focuses on Venrock’s public and cross-over biotech fund. Prior to joining Venrock, Mr. Cahill was a co-founder and Chief Development Officer at Simpirica Spine, Inc. “Simpirica”, a Bay Area medical device company focused on the development and commercialization of devices for spinal stabilization. Mr. Cahill also served as Simpirica’s Chief Executive Officer from 2006 until 2009. Prior to graduate school, Mr. Cahill worked at the Boston Consulting Group as a strategy consultant. Mr. Cahill received a M.B.A. from the Stanford Graduate School of Business and his M.S. in biological sciences from Stanford University. Mr. Cahill received his B.A. and B.S. in biological sciences and economics, respectively, from Stanford University. - Colin Cahill自2015年5月以来一直担任我们的董事会成员。Cahill先生自2012年以来一直担任Venrock的副总裁，并专注于Venrock&8217；的公共和交叉生物技术基金。在加入Venrock之前，Cahill先生是Simpirica Spine，Inc.的联合创始人兼首席开发官，Simpirica&8221；是一家湾区医疗设备公司，专注于脊柱稳定设备的开发和商业化。从2006年到2009年，Cahill先生还担任Simpirica&8217；的首席执行官。在研究生院之前，Cahill先生在波士顿咨询集团（Boston Consulting Group）工作，担任战略顾问。Cahill先生在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，并在斯坦福大学（Stanford University）获得生物科学硕士学位。Cahill先生分别在斯坦福大学（Stanford University）获得生物科学和经济学的学士学位和学士学位。
- Colin Cahill has served as a member of our board of directors since May 2015. Mr. Cahill has been Vice-President of Venrock since 2012 and focuses on Venrock’s public and cross-over biotech fund. Prior to joining Venrock, Mr. Cahill was a co-founder and Chief Development Officer at Simpirica Spine, Inc. “Simpirica”, a Bay Area medical device company focused on the development and commercialization of devices for spinal stabilization. Mr. Cahill also served as Simpirica’s Chief Executive Officer from 2006 until 2009. Prior to graduate school, Mr. Cahill worked at the Boston Consulting Group as a strategy consultant. Mr. Cahill received a M.B.A. from the Stanford Graduate School of Business and his M.S. in biological sciences from Stanford University. Mr. Cahill received his B.A. and B.S. in biological sciences and economics, respectively, from Stanford University.
- Marc Andre Marcotte
-
Marc Andre Marcotte自2018年8月以来一直担任我们的董事会成员。他担任Sector Asset Management Inc.的合伙人，他于2006年加入该公司。在那里，Marcotte先生自2018年4月起担任首席运营官。在担任现职之前，Marcotte先生于2013年12月至2018年4月担任Sector Asset Management的董事总经理。在Sectoral Asset Management Inc.之前，Marcotte先生曾在Cryocath Technologies，Inc.担任质量总监。在此之前，Marcotte先生曾在温哥华的Aerial Vascular Engineering担任血管成形术导管和支架的工程师。Marcotte先生自2010年以来一直是C.F.A.Charterholder。Marcotte先生于1997年毕业于舍布鲁克大学（Sherbrooke University），获得学士学位，并于2004年在蒙特利尔高等商学院（HEC Montreal）获得工商管理硕士学位。Marcotte先生作为一家梦百合投资公司合伙人的前景，以及他在梦百合行业的经验，为他提供了在我们董事会任职的资格和技能。Marcotte先生将在本招股说明书构成部分的注册声明生效之前立即辞去我们的董事会职务。由于Marcotte先生是Sector Asset Management Inc.的合伙人，该公司的政策禁止Marcotte先生担任该公司投资组合公司的上市公司的董事会成员。
Marc Andre Marcotte has served as a member of our board of directors since August 2018. He serves as Partner at Sectoral Asset Management Inc., which he joined in 2006. There, Mr. Marcotte has been Chief Operating Officer since April 2018. Prior to his current position, Mr. Marcotte was a Managing Director of Sectoral Asset Management from December 2013 to April 2018. Prior to Sectoral Asset Management Inc., Mr. Marcotte served at CryoCath Technologies, Inc. as the Director of Quality. Prior to that, Mr. Marcotte worked at Arterial Vascular Engineering in Vancouver as an engineer on angioplasty catheters and stents. Mr. Marcotte has been a C.F.A. charterholder since 2010. Mr. Marcotte graduated from Sherbrooke University in 1997 with a B.E. and completed a M.B.A. at HEC Montreal in 2004. Mr. Marcotte’s perspective as a partner of a healthcare investment firm, along with his experience in the healthcare industry, provides him with the qualifications and skills to serve on our board of directors. Mr. Marcotte will resign from our board of directors effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. As Mr. Marcotte is a partner at Sectoral Asset Management Inc., the firm’s policy prohibits Mr. Marcotte from serving on the board of directors of a public company of the firm’s portfolio companies. - Marc Andre Marcotte自2018年8月以来一直担任我们的董事会成员。他担任Sector Asset Management Inc.的合伙人，他于2006年加入该公司。在那里，Marcotte先生自2018年4月起担任首席运营官。在担任现职之前，Marcotte先生于2013年12月至2018年4月担任Sector Asset Management的董事总经理。在Sectoral Asset Management Inc.之前，Marcotte先生曾在Cryocath Technologies，Inc.担任质量总监。在此之前，Marcotte先生曾在温哥华的Aerial Vascular Engineering担任血管成形术导管和支架的工程师。Marcotte先生自2010年以来一直是C.F.A.Charterholder。Marcotte先生于1997年毕业于舍布鲁克大学（Sherbrooke University），获得学士学位，并于2004年在蒙特利尔高等商学院（HEC Montreal）获得工商管理硕士学位。Marcotte先生作为一家梦百合投资公司合伙人的前景，以及他在梦百合行业的经验，为他提供了在我们董事会任职的资格和技能。Marcotte先生将在本招股说明书构成部分的注册声明生效之前立即辞去我们的董事会职务。由于Marcotte先生是Sector Asset Management Inc.的合伙人，该公司的政策禁止Marcotte先生担任该公司投资组合公司的上市公司的董事会成员。
- Marc Andre Marcotte has served as a member of our board of directors since August 2018. He serves as Partner at Sectoral Asset Management Inc., which he joined in 2006. There, Mr. Marcotte has been Chief Operating Officer since April 2018. Prior to his current position, Mr. Marcotte was a Managing Director of Sectoral Asset Management from December 2013 to April 2018. Prior to Sectoral Asset Management Inc., Mr. Marcotte served at CryoCath Technologies, Inc. as the Director of Quality. Prior to that, Mr. Marcotte worked at Arterial Vascular Engineering in Vancouver as an engineer on angioplasty catheters and stents. Mr. Marcotte has been a C.F.A. charterholder since 2010. Mr. Marcotte graduated from Sherbrooke University in 1997 with a B.E. and completed a M.B.A. at HEC Montreal in 2004. Mr. Marcotte’s perspective as a partner of a healthcare investment firm, along with his experience in the healthcare industry, provides him with the qualifications and skills to serve on our board of directors. Mr. Marcotte will resign from our board of directors effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. As Mr. Marcotte is a partner at Sectoral Asset Management Inc., the firm’s policy prohibits Mr. Marcotte from serving on the board of directors of a public company of the firm’s portfolio companies.
- Douglas Godshall
-
Douglas Godshall自2006年9月担任首席执行官，自2006年10月担任董事。在加入HeartWare前，Godshall先生在自1990年在Boston Scientific担任各种执行和管理职务，包括担任一些Boston Scientific运营委员会职务，以及自2005年1月担任负责血管手术的总裁。此前，Godshall先生在Boston Scientific担任了5年的负责业务开发的副总裁，任职期间他关注于心脏病学、电生理学、神经辐射学以及血管手术部门的收购策略。Godshall先生自2012年3月任职于pSivida Corp.，该公司是一家在纳斯达克（NASDAQ）和澳洲证券交易所（ASX）上市的公司，该公司关注于小型、可注射药物传送系统的开发；同时自2013年5月任职于Vital Therapies, Inc.，该公司是一家为肝病疗治疗开发以细胞为基础的疗法的私人公司。另外，Godshall先生将会在2014年5月加入医疗设备生产商协会（Medical Device Manufacturers Association）董事会，该协会是一个全国性的贸易协会。Godshall先生从拉斐特学院（Lafayette College）获得学士学位，从马塞诸塞州波士顿市东北大学（Northeastern University in Boston）获得工商管理学硕士学位。
Douglas Godshall has served as our President and Chief Executive Officer and as a member of our board of directors since May 2017. Previously, Mr. Godshall served as the Chief Executive Officer of HeartWare International, Inc. “HeartWare”, a Nasdaq-listed company, from September 2006 until August 2016 and as director from October 2006 until its acquisition by Medtronic plc in August 2016. Prior to joining HeartWare, Mr. Godshall served in various executive, managerial and leadership positions at Boston Scientific Corporation “Boston Scientific”, where he had been employed since 1990. Mr. Godshall also serves on the board of directors of Eyepoint Pharmaceuticals, Inc. Mr. Godshall has a B.A. in Business from Lafayette College and M.B.A from Northeastern University. - Douglas Godshall自2006年9月担任首席执行官，自2006年10月担任董事。在加入HeartWare前，Godshall先生在自1990年在Boston Scientific担任各种执行和管理职务，包括担任一些Boston Scientific运营委员会职务，以及自2005年1月担任负责血管手术的总裁。此前，Godshall先生在Boston Scientific担任了5年的负责业务开发的副总裁，任职期间他关注于心脏病学、电生理学、神经辐射学以及血管手术部门的收购策略。Godshall先生自2012年3月任职于pSivida Corp.，该公司是一家在纳斯达克（NASDAQ）和澳洲证券交易所（ASX）上市的公司，该公司关注于小型、可注射药物传送系统的开发；同时自2013年5月任职于Vital Therapies, Inc.，该公司是一家为肝病疗治疗开发以细胞为基础的疗法的私人公司。另外，Godshall先生将会在2014年5月加入医疗设备生产商协会（Medical Device Manufacturers Association）董事会，该协会是一个全国性的贸易协会。Godshall先生从拉斐特学院（Lafayette College）获得学士学位，从马塞诸塞州波士顿市东北大学（Northeastern University in Boston）获得工商管理学硕士学位。
- Douglas Godshall has served as our President and Chief Executive Officer and as a member of our board of directors since May 2017. Previously, Mr. Godshall served as the Chief Executive Officer of HeartWare International, Inc. “HeartWare”, a Nasdaq-listed company, from September 2006 until August 2016 and as director from October 2006 until its acquisition by Medtronic plc in August 2016. Prior to joining HeartWare, Mr. Godshall served in various executive, managerial and leadership positions at Boston Scientific Corporation “Boston Scientific”, where he had been employed since 1990. Mr. Godshall also serves on the board of directors of Eyepoint Pharmaceuticals, Inc. Mr. Godshall has a B.A. in Business from Lafayette College and M.B.A from Northeastern University.
- C. Raymond Larkin, Jr.
-
C. Raymond Larkin, Jr.自2008年10月担任HeartWare的董事，自2010年6月担任董事会主席。Larkin先生在2004年3月加入Align Technology, Inc.（纳斯达克（Nasdaq）代码：ALGN）董事会，自2006年6月担任董事会主席。Align Technology专注于新型畸齿矫正产品的设计、生产和市场营销。他是Neuropace和TherOx的董事，前者是一家私有的可植入设备的生产商，这些设备主要用于治疗神经紊乱；后者是一家专注于治疗心脏病患者组织缺氧问题的企业。此前，从1999年到2007年5月，Larkin先生从2002年到2012年任职于Davita, Inc.以及Novasys Medical, Inc.董事会，前者是一家纽交所上市的透析服务提供商；后者是一家专注于女性健康创新性疗法开发的私有企业。自2006年7月，Larkin先生在Cutlass Capital担任风险合伙人，该公司是一家健康护理风险资本公司，同时自2002年1月在Synecor担任执行委员会成员，该公司是一家创新性早期医疗技术开发公司。Larkin先生在Nellcor Puritan Bennett, Inc（重要护理设备生产公司）任职大约15年，他1983年加入该公司并担任负责销售和市场营销的副总裁。他在1989年被任命为Nellcor的总裁以及首席执行官。Larkin先生随后担任Eunoe, Inc.的董事会主席以及首席执行官，该公司是一家专注于神经紊乱的公司，他一直担任此职务到2005年该公司被Integra LifeSciences Holdings Corporation收购。Larkin先生，拉萨尔大学（LaSalle University）工业管理学，同时是美国海军陆战队前上校。
C. Raymond Larkin, Jr. currently serves as a principal of Group Outcome L.L.C., a merchant banking firm concentrating on medical technologies. Previously, Mr. Larkin was Chairman and CEO at Eunoe, Inc. He also served as a part time Venture Partner at Cutlass Capital, from 2001 to 2007. Prior to Eunoe, Inc, he was President and CEO of Nellcor Puritan Bennett, Inc., a respiratory product company, which grew to nearly $1 billion in revenues during his tenure through the development and introduction of pulse oximetry for patient safety monitoring.Mr. Larkin earned his B.S. degree in Industrial Management from LaSalle University and served in the United States Marine Corps, rising to the level of Capitan. - C. Raymond Larkin, Jr.自2008年10月担任HeartWare的董事，自2010年6月担任董事会主席。Larkin先生在2004年3月加入Align Technology, Inc.（纳斯达克（Nasdaq）代码：ALGN）董事会，自2006年6月担任董事会主席。Align Technology专注于新型畸齿矫正产品的设计、生产和市场营销。他是Neuropace和TherOx的董事，前者是一家私有的可植入设备的生产商，这些设备主要用于治疗神经紊乱；后者是一家专注于治疗心脏病患者组织缺氧问题的企业。此前，从1999年到2007年5月，Larkin先生从2002年到2012年任职于Davita, Inc.以及Novasys Medical, Inc.董事会，前者是一家纽交所上市的透析服务提供商；后者是一家专注于女性健康创新性疗法开发的私有企业。自2006年7月，Larkin先生在Cutlass Capital担任风险合伙人，该公司是一家健康护理风险资本公司，同时自2002年1月在Synecor担任执行委员会成员，该公司是一家创新性早期医疗技术开发公司。Larkin先生在Nellcor Puritan Bennett, Inc（重要护理设备生产公司）任职大约15年，他1983年加入该公司并担任负责销售和市场营销的副总裁。他在1989年被任命为Nellcor的总裁以及首席执行官。Larkin先生随后担任Eunoe, Inc.的董事会主席以及首席执行官，该公司是一家专注于神经紊乱的公司，他一直担任此职务到2005年该公司被Integra LifeSciences Holdings Corporation收购。Larkin先生，拉萨尔大学（LaSalle University）工业管理学，同时是美国海军陆战队前上校。
- C. Raymond Larkin, Jr. currently serves as a principal of Group Outcome L.L.C., a merchant banking firm concentrating on medical technologies. Previously, Mr. Larkin was Chairman and CEO at Eunoe, Inc. He also served as a part time Venture Partner at Cutlass Capital, from 2001 to 2007. Prior to Eunoe, Inc, he was President and CEO of Nellcor Puritan Bennett, Inc., a respiratory product company, which grew to nearly $1 billion in revenues during his tenure through the development and introduction of pulse oximetry for patient safety monitoring.Mr. Larkin earned his B.S. degree in Industrial Management from LaSalle University and served in the United States Marine Corps, rising to the level of Capitan.
高管简历
中英对照 | 中文 | 英文- Dan Puckett
Dan Puckett自2016年4月起担任我们的首席财务官，自2018年11月起担任我们的秘书。在加入Shockwave Medical之前，Puckett先生于2015年6月至2016年4月担任Counsyl（一家风险投资支持的DNA检测和基因咨询公司）的首席财务官。Puckett从2011年到2015年6月担任分子诊断公司AriosaDiagnostics，Inc.“；Ariosa”；首席财务官，直到2015年6月。Ariosa于2015年1月被Roche收购。Puckett先生于2011年9月从森林实验室公司来到Ariosa，担任森林实验室公司子公司Cerexa，Inc.的运营执行董事。在加入Cerexa，Inc.之前，Puckett先生曾在Affymetrix，Inc.和AOL担任高级财务和运营职位。Puckett先生拥有旧金山大学（University of San Francisco）的工商管理硕士学位和华盛顿州立大学（Washington State University）的会计学学士学位。
Dan Puckett has served as our Chief Financial Officer since April 2016 and has served as our Secretary since November 2018. Prior to joining ShockWave Medical, from June 2015 to April 2016 Mr. Puckett served as Chief Financial Officer for Counsyl, a venture backed DNA testing and genetic counseling company. From 2011 to June 2015 Mr. Puckett served as Chief Financial Officer for Ariosa Diagnostics, Inc. “Ariosa”, a molecular diagnostics company, until June 2015. Ariosa was acquired by Roche in January 2015. Mr. Puckett came to Ariosa from Forest Laboratories, Inc. in September 2011 where he served as Executive Director, Operations of Cerexa, Inc., a Forest Laboratories, Inc. subsidiary. Prior to Cerexa, Inc., Mr. Puckett held senior finance and operations positions at Affymetrix, Inc. and AOL. Mr. Puckett holds an M.B.A. from the University of San Francisco and a B.A. in Accounting from Washington State University.- Dan Puckett自2016年4月起担任我们的首席财务官，自2018年11月起担任我们的秘书。在加入Shockwave Medical之前，Puckett先生于2015年6月至2016年4月担任Counsyl（一家风险投资支持的DNA检测和基因咨询公司）的首席财务官。Puckett从2011年到2015年6月担任分子诊断公司AriosaDiagnostics，Inc.“；Ariosa”；首席财务官，直到2015年6月。Ariosa于2015年1月被Roche收购。Puckett先生于2011年9月从森林实验室公司来到Ariosa，担任森林实验室公司子公司Cerexa，Inc.的运营执行董事。在加入Cerexa，Inc.之前，Puckett先生曾在Affymetrix，Inc.和AOL担任高级财务和运营职位。Puckett先生拥有旧金山大学（University of San Francisco）的工商管理硕士学位和华盛顿州立大学（Washington State University）的会计学学士学位。
- Dan Puckett has served as our Chief Financial Officer since April 2016 and has served as our Secretary since November 2018. Prior to joining ShockWave Medical, from June 2015 to April 2016 Mr. Puckett served as Chief Financial Officer for Counsyl, a venture backed DNA testing and genetic counseling company. From 2011 to June 2015 Mr. Puckett served as Chief Financial Officer for Ariosa Diagnostics, Inc. “Ariosa”, a molecular diagnostics company, until June 2015. Ariosa was acquired by Roche in January 2015. Mr. Puckett came to Ariosa from Forest Laboratories, Inc. in September 2011 where he served as Executive Director, Operations of Cerexa, Inc., a Forest Laboratories, Inc. subsidiary. Prior to Cerexa, Inc., Mr. Puckett held senior finance and operations positions at Affymetrix, Inc. and AOL. Mr. Puckett holds an M.B.A. from the University of San Francisco and a B.A. in Accounting from Washington State University.
- Isaac Zacharias
Isaac Zacharias自2018年11月起担任我们的首席商务官。此前，Zacharias先生于2018年3月至2018年11月担任我们的结构心脏总经理兼国际销售Vice President。在加入Shockwave Medical之前，Zacharias先生于2011年7月至2018年3月担任波士顿科学PCI指导业务Vice President兼总经理。在此之前，Zacharias先生还担任波士顿科学公司（Boston Scientific）负责新业务开发的Vice President，他在该公司就心脏病学、节律管理和血管业务部门的投资和收购进行了谈判。Zacharias先生的职业生涯始于担任研发工程师，并担任过各种临床和营销职务。Zacharias先生拥有加州大学戴维斯分校（University of California，Davis）的机械工程学士学位和硕士学位。
Isaac Zacharias has served as our Chief Commercial Officer since November 2018. Previously, Mr. Zacharias served as our General Manager of Structural Heart and Vice President of International Sales from March 2018 to November 2018. Prior to joining Shockwave Medical, Mr. Zacharias served as the Vice President, General Manager for the PCI Guidance business at Boston Scientific from July 2011 to March 2018. Prior to that, Mr. Zacharias also served as the Vice President, New Business Development for Boston Scientific where he negotiated investments and acquisitions for the Cardiology, Rhythm Management and Vascular business units. Mr. Zacharias began his career as an R&D engineer and has held a variety of clinical and marketing roles. Mr. Zacharias holds B.S. and M.S. degrees in Mechanical Engineering from the University of California, Davis.- Isaac Zacharias自2018年11月起担任我们的首席商务官。此前，Zacharias先生于2018年3月至2018年11月担任我们的结构心脏总经理兼国际销售Vice President。在加入Shockwave Medical之前，Zacharias先生于2011年7月至2018年3月担任波士顿科学PCI指导业务Vice President兼总经理。在此之前，Zacharias先生还担任波士顿科学公司（Boston Scientific）负责新业务开发的Vice President，他在该公司就心脏病学、节律管理和血管业务部门的投资和收购进行了谈判。Zacharias先生的职业生涯始于担任研发工程师，并担任过各种临床和营销职务。Zacharias先生拥有加州大学戴维斯分校（University of California，Davis）的机械工程学士学位和硕士学位。
- Isaac Zacharias has served as our Chief Commercial Officer since November 2018. Previously, Mr. Zacharias served as our General Manager of Structural Heart and Vice President of International Sales from March 2018 to November 2018. Prior to joining Shockwave Medical, Mr. Zacharias served as the Vice President, General Manager for the PCI Guidance business at Boston Scientific from July 2011 to March 2018. Prior to that, Mr. Zacharias also served as the Vice President, New Business Development for Boston Scientific where he negotiated investments and acquisitions for the Cardiology, Rhythm Management and Vascular business units. Mr. Zacharias began his career as an R&D engineer and has held a variety of clinical and marketing roles. Mr. Zacharias holds B.S. and M.S. degrees in Mechanical Engineering from the University of California, Davis.
- Douglas Godshall
Douglas Godshall自2006年9月担任首席执行官，自2006年10月担任董事。在加入HeartWare前，Godshall先生在自1990年在Boston Scientific担任各种执行和管理职务，包括担任一些Boston Scientific运营委员会职务，以及自2005年1月担任负责血管手术的总裁。此前，Godshall先生在Boston Scientific担任了5年的负责业务开发的副总裁，任职期间他关注于心脏病学、电生理学、神经辐射学以及血管手术部门的收购策略。Godshall先生自2012年3月任职于pSivida Corp.，该公司是一家在纳斯达克（NASDAQ）和澳洲证券交易所（ASX）上市的公司，该公司关注于小型、可注射药物传送系统的开发；同时自2013年5月任职于Vital Therapies, Inc.，该公司是一家为肝病疗治疗开发以细胞为基础的疗法的私人公司。另外，Godshall先生将会在2014年5月加入医疗设备生产商协会（Medical Device Manufacturers Association）董事会，该协会是一个全国性的贸易协会。Godshall先生从拉斐特学院（Lafayette College）获得学士学位，从马塞诸塞州波士顿市东北大学（Northeastern University in Boston）获得工商管理学硕士学位。
Douglas Godshall has served as our President and Chief Executive Officer and as a member of our board of directors since May 2017. Previously, Mr. Godshall served as the Chief Executive Officer of HeartWare International, Inc. “HeartWare”, a Nasdaq-listed company, from September 2006 until August 2016 and as director from October 2006 until its acquisition by Medtronic plc in August 2016. Prior to joining HeartWare, Mr. Godshall served in various executive, managerial and leadership positions at Boston Scientific Corporation “Boston Scientific”, where he had been employed since 1990. Mr. Godshall also serves on the board of directors of Eyepoint Pharmaceuticals, Inc. Mr. Godshall has a B.A. in Business from Lafayette College and M.B.A from Northeastern University.- Douglas Godshall自2006年9月担任首席执行官，自2006年10月担任董事。在加入HeartWare前，Godshall先生在自1990年在Boston Scientific担任各种执行和管理职务，包括担任一些Boston Scientific运营委员会职务，以及自2005年1月担任负责血管手术的总裁。此前，Godshall先生在Boston Scientific担任了5年的负责业务开发的副总裁，任职期间他关注于心脏病学、电生理学、神经辐射学以及血管手术部门的收购策略。Godshall先生自2012年3月任职于pSivida Corp.，该公司是一家在纳斯达克（NASDAQ）和澳洲证券交易所（ASX）上市的公司，该公司关注于小型、可注射药物传送系统的开发；同时自2013年5月任职于Vital Therapies, Inc.，该公司是一家为肝病疗治疗开发以细胞为基础的疗法的私人公司。另外，Godshall先生将会在2014年5月加入医疗设备生产商协会（Medical Device Manufacturers Association）董事会，该协会是一个全国性的贸易协会。Godshall先生从拉斐特学院（Lafayette College）获得学士学位，从马塞诸塞州波士顿市东北大学（Northeastern University in Boston）获得工商管理学硕士学位。
- Douglas Godshall has served as our President and Chief Executive Officer and as a member of our board of directors since May 2017. Previously, Mr. Godshall served as the Chief Executive Officer of HeartWare International, Inc. “HeartWare”, a Nasdaq-listed company, from September 2006 until August 2016 and as director from October 2006 until its acquisition by Medtronic plc in August 2016. Prior to joining HeartWare, Mr. Godshall served in various executive, managerial and leadership positions at Boston Scientific Corporation “Boston Scientific”, where he had been employed since 1990. Mr. Godshall also serves on the board of directors of Eyepoint Pharmaceuticals, Inc. Mr. Godshall has a B.A. in Business from Lafayette College and M.B.A from Northeastern University.